1. Home
  2. ALLO vs NPCE Comparison

ALLO vs NPCE Comparison

Compare ALLO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.32

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Logo Neuropace Inc.

NPCE

Neuropace Inc.

HOLD

Current Price

$16.94

Market Cap

432.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLO
NPCE
Founded
2017
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
539.4M
432.3M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ALLO
NPCE
Price
$2.32
$16.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
6
Target Price
$8.35
$18.33
AVG Volume (30 Days)
14.4M
147.5K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
34.09
29.03
EPS
N/A
N/A
Revenue
N/A
$99,986,000.00
Revenue This Year
N/A
$0.90
Revenue Next Year
$142,416.42
$24.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.13
52 Week Low
$0.86
$7.56
52 Week High
$4.46
$18.97

Technical Indicators

Market Signals
Indicator
ALLO
NPCE
Relative Strength Index (RSI) 47.27 70.21
Support Level $1.92 $15.25
Resistance Level $2.71 $16.96
Average True Range (ATR) 0.35 0.65
MACD -0.04 0.24
Stochastic Oscillator 17.82 75.60

Price Performance

Historical Comparison
ALLO
NPCE

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About NPCE Neuropace Inc.

NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Share on Social Networks: